79 completed, 12 unknown, 10 recruiting, 7 terminated. 34 Phase 4, 26 Phase 3, 18 Not applicable, 11 Phase 2, 5 Phase 1.
Follow Kirby Institute: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| Optimised Dalbavancin Dosing for Serious Gram-Positive Bacterial Infections dalbavancin - Serious Gram-Positive Bacterial Infections | Not yet recruiting | Kirby Institute | 50 | 2027-01-01 | 2026-10-05 | |
| Swabs in Screening for HPV (SWISH) Self-collected anal swab - Anal Cancer, Human Papilloma Virus (HPV) | Not applicable | Not yet recruiting | Kirby Institute | 700 | 2026-11-01 | 2026-08-27 |
| Better Options for Lymphatic Filariasis Treatment MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole - Lymphatic Filariasis, Scabies | Phase 3 | Recruiting | Medicines Development for Global Health | 5100 | 2026-09-28 | 2026-10-07 |
| Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study 12 weeks of weekly subcutaneous semaglutide injection - Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | Kirby Institute | 40 | 2026-09-01 | 2026-06-26 |
| Oritavancin for Treatment of Serious Cardiac Infections Oritavancin - Infective Endocarditis, Cardiac Device Infection | Phase 2 | Not yet recruiting | Kirby Institute | 20 | 2026-07-01 | 2026-04-29 |
| The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory Respiratory Syncytial Virus (RSV) Infection, Respiratory Syncytial Virus Hospitalizations | Completed | Nicola Irwin | 2792 | 2025-09-22 | 2026-03-05 | |
| Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases Moxidectin, Ivermectin - Onchocerciasis, Ascaris Lumbricoides Infection | Phase 4 | Recruiting | Kirby Institute | 52000 | 2025-08-04 | 2025-11-21 |
| Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) Dapagliflozin 10mg Tab, Pitavastatin 4 Mg Oral Tablet, Rosuvastatin and Ezetimibe - HIV Infections, Weight Gain | Phase 3 | Active not recruiting | Kirby Institute | 300 | 2024-12-16 | 2026-07-22 |
| Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons NIATx - HIV, Hepatitis C Virus (HCV) | Not applicable | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 548 | 2024-10-01 | 2025-12-29 |
| PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised. Observational - Invasive Fungal Infections, Invasive Bacterial Infection | Not yet recruiting | Kirby Institute | 300 | 2024-03-01 | 2024-02-20 | |
| MENJAGA: Continuous Quality Improvement for Antenatal HIV, Syphilis and Hepatitis B Testing in Indonesia Continuous quality improvement - Hiv, Syphilis | Not applicable | Unknown | Yanri Wijayanti Subronto, MD, PhD, | 2000 | 2023-10-01 | 2023-09-28 |
| National Prisons Hepatitis Education Project: Research Evaluation Education Intervention (The HepPEd Program) - HCV | Not applicable | Unknown | Kirby Institute | 3000 | 2023-09-04 | 2024-03-06 |
| Immunosuppression and COVID-19 Boosters diphtheria and tetanus toxoids (adsorbed) vaccine, COVID-19 vaccine - COVID-19 | Phase 3 | Recruiting | Kirby Institute | 320 | 2023-07-21 | 2026-02-24 |
| The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset Diagnostic Test: Point-of-Care Testing - Hepatitis C | Recruiting | Kirby Institute | 40000 | 2023-02-23 | 2026-09-28 | |
| The National Australian HCV Point-of-Care Testing Program - Minimal Dataset Point-of-Care Testing - Hepatitis C | Recruiting | Kirby Institute | 80000 | 2023-01-23 | 2026-09-28 | |
| Evaluation of Hepatitis B Virus (HBV) DNA Test As Point of Care Tool GeneXpert HBV DNA Viral Load Assay, Dried Blood Spot HBV DNA test - Hepatitis B | Completed | Kirby Institute | 268 | 2022-11-17 | 2025-03-06 | |
| A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs Incentive payment - Hepatitis C, Chronic | Not applicable | Unknown | Kirby Institute | 400 | 2022-10-01 | 2022-04-14 |
| Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs Xpert HCV Viral Load Fingerstick, Aptima HCV Quant DX Assay - Hepatitis C, Hepatitis C, Chronic | Not applicable | Completed | Kirby Institute | 1801 | 2022-07-27 | 2026-06-03 |
| Australian Hepatitis and Risk Survey in Prisons Point-of-care hepatitis C antibody test, Point-of-care hepatitis C RNA test, Point-of-care hepatitis B surface antibody test - Hepatitis C, Hepatitis B | Unknown | Kirby Institute | 2400 | 2022-04-27 | 2023-05-03 |
Showing 20 of 124. Sign in to see all of them.
HIV Infections (31) · Hepatitis C (29) · COVID-19 (14) · Coronavirus Infections (12) · RNA Virus Infections (12) · Coronaviridae Infections (11) · Hepatitis C, Chronic (11) · Nidovirales Infections (11) · Severe Acute Respiratory Syndrome (11) · Virus Diseases (11) · Acquired Immunodeficiency Syndrome (10) · Hepatitis B (9) · Hepatitis (5) · Cardiovascular Diseases (4) · Lipodystrophy (4)
Tenofovir (9) · remdesivir (9) · Lamivudine (8) · Ritonavir (8) · Ribavirin (7) · Sofosbuvir (7) · efavirenz (7) · Emtricitabine (6) · Lopinavir (6) · Zidovudine (6) · Darunavir (5) · Raltegravir Potassium (5) · abacavir (5) · Atazanavir Sulfate (4) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (4)
Australia (77) · Thailand (24) · United Kingdom (18) · United States (15) · Argentina (12) · Switzerland (10) · Germany (9) · Malaysia (9) · Nigeria (9) · Spain (9) · Uganda (9) · Denmark (8) · Singapore (8) · South Africa (8) · India (7)
David A Cooper, MD (6) · James Neaton, Prof. (6) · Jens Lundgren, Prof. (6) · Prof. James Neaton (4) · Andrew D Carr, MD (3) · Mark Polizzotto, MD, PhD (3) · Samuel Brown, MD (3) · David A Cooper, AO DSc MD FRACP FRCPA FRCP (2) · David Cooper, MD, PhD (2) · Dominic Dwyer (2) · Gail Matthews, MD (2) · Gregory Dore, MBBS, PhD (2) · Jason Grebely (2) · Kiat Ruxrungtham, MD (2) · Mark Polizzotto, MD (2)
PMID 24204757, PMID 26867206, PMID 31300820, PMID 32166305, PMID 33356051, PMID 34928698, PMID 34953520, PMID 35817072, PMID 35939810, PMID 17479946, PMID 18697216, PMID 19842973, PMID 20146627, PMID 20735258, PMID 20864808, PMID 21145855, PMID 21172791, PMID 21282185, PMID 21860347, PMID 21930607, PMID 21951596, PMID 22405335, PMID 22410637, PMID 22713478, PMID 23596247, PMID 23769235, PMID 23921615, PMID 23970149, PMID 24130889, PMID 24522178, PMID 24681993, PMID 24722774, PMID 24730732, PMID 25105742, PMID 25139018, PMID 25501988, PMID 25711317, PMID 25711318, PMID 25711319, PMID 25711320, PMID 25711321, PMID 25711322, PMID 25711323, PMID 25711324, PMID 25711325, PMID 25711326, PMID 25711327, PMID 25711328, PMID 25711329, PMID 25711330
2008 (1), R01HL065953 (1), U01AI068641 (1), U01AI195193 (1)